Phanes Biotech

Executive Summary

Phanes Biotech is a private San Diego-based biotechnology company focused on developing therapies for Alzheimer's disease (AD), a devastating neurodegenerative condition affecting 44 million people worldwide and projected to reach 131.5 million by 2050. Leveraging expertise across antibodies, biologics, and small molecules, the company aims to address the massive unmet need in AD, which remains the sixth leading cause of death in the U.S. with no disease-modifying treatments widely available. Founded in 2018, Phanes operates in a highly competitive landscape but has not disclosed specific pipeline candidates, financials, or clinical stage, suggesting it is at an early, preclinical stage of development. The company's multi-modal approach could provide differentiation, but the lack of public data makes it difficult to assess its scientific and commercial potential. With few details on partnerships, funding, or regulatory milestones, Phanes Biotech remains a high-risk, early-stage opportunity in the Alzheimer's space.